Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 13/20 | 0.60 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.58 |
| ▸ | MAOA | P21397 | 9/20 | 0.54 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.50 |
| ▸ | CASP1 | P29466 | 1/20 | 0.49 |
| ▸ | CASP7 | P55210 | 1/20 | 0.49 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6825249 | 0.90 | MAOB (0.66) | MAOBHRH3MAOA | |
| SCHEMBL14604954 | 0.87 | MAOB (0.65) | MAOBHRH3MAOABRD4 | |
| SCHEMBL8272631 | 0.87 | MAOB (0.69) | MAOBHRH3MAOAMAPTL3MBTL1 | |
| SCHEMBL6391911 | 0.86 | BRD4 (0.64) | MAOBHRH3MAOAMAPTL3MBTL1 | |
| SCHEMBL27974960 | 0.84 | MAOB (0.66) | MAOBHRH3MAOAMAPTL3MBTL1 | |
| SCHEMBL9740545 | 0.83 | MAOB (0.57) | MAOBHRH3MAOACASP1CASP7 | |
| SCHEMBL1030417 | 0.83 | MAOB (0.64) | MAOBHRH3MAOAMAPTL3MBTL1 | |
| SCHEMBL29090878 | 0.83 | MAOB (0.60) | MAOBHRH3MAOACASP1CASP7 | |
| SCHEMBL13256055 | 0.82 | BRD4 (0.60) | MAOBHRH3MAOAMAPTL3MBTL1 | |
| SCHEMBL4815741 | 0.82 | MAOB (0.63) | MAOBHRH3MAOA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| US-8742106-B2 | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG (CH) | 2014-06-03 | — | — | US | disclosed |
| EP-2516437-B1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2516437-B1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2014-01-29 | — | — | EP | disclosed |
| EP-2516437-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | Novartis AG (CH) | 2012-10-31 | — | — | EP | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2012-10-11 | — | — | US | disclosed |
| WO-2011076744-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| WO-2011076744-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | NOVARTIS AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| US-20090105278-A1 | Selective inhibitors of human corticosteroid syntheses | UNIVERSITAT DES SAARLANDES (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105278-A1 | Selective inhibitors of human corticosteroid syntheses | UNIVERSITAT DES SAARLANDES (DE) | 2009-04-23 | — | — | US | disclosed |
| US-20090105278-A1 | Selective inhibitors of human corticosteroid syntheses | UNIVERSITAT DES SAARLANDES (DE) | 2009-04-23 | — | — | US | disclosed |
| WO-2006008316-A2 | SELECTIVE INHIBITORS OF HUMAN CORTICOSTEROID SYNTHESES | Universität des Saarlandes (DE) | 2006-01-26 | — | — | WO | disclosed |
| US-6716852-B2 | FOR THERAPY OF ARTERIAL HYPERTENSION AND CARDIOVASCULAR DISEASES | LES LABORATORIES SERVIER (FR) | 2004-04-06 | — | — | US | disclosed |
| EP-1255757-B1 | AMINO ACID DERIVATIVES AND USE THEREOF AS NEP, ACE AND ECE INHIBITORS | INST NAT SANTE RECH MED (FR) | 2003-06-18 | — | — | EP | disclosed |
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | LES LABORATOIRES SERVIER (FR) | 2003-03-20 | — | — | US | disclosed |
| EP-1255757-A1 | AMINO ACID DERIVATIVES AND USE THEREOF AS NEP, ACE AND ECE INHIBITORS | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2002-11-13 | — | — | EP | disclosed |
| WO-2001060822-A1 | AMINO ACID DERIVATIVES AND USE THEREOF AS NEP, ACE AND ECE INHIBITORS | INSTITUT NATIONAL DE LA RECHERCHE MEDICALE INSERM (FR) | 2001-08-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120258973-A1 | DISUBSTITUTED HETEROARYL-FUSED PYRIDINES | CYP4F2, CYP11B2, CYP4F3 | MAOB 221/4885HRH3 580/4885MAOA 272/4885 |
| US-20090105278-A1 | Selective inhibitors of human corticosteroid syntheses | HSD11B1, HSD11B2, CYP11B1 | MAOB 456/4885HRH3 3461/4885MAOA 1449/4885 |
| US-20030055086-A1 | Amino acid derivatives and use thereof as nep, ace and ece inhibitors | MME, ACE, ECE1 | MAOB 84/4885HRH3 269/4885MAOA 81/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.